Compare Stocks: ANRO, OGN, TARS, and RGC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$22.51 -4.1%	$28.28	$10.20 ▼ $37.48	$886.87M	1.31	626,044 shs	484,410 shs
OGN Organon & Co.	$13.83 +0.1%	$13.74	$5.69 ▼ $13.84	$3.63B	1.55	2.28 million shs	1.85 million shs
RGC Regencell Bioscience	$6.71 -2.2%	$6.83	$4.51 ▼ $69.00	$3.33B	1.18	437,837 shs	147,668 shs
TARS Tarsus Pharmaceuticals	$74.85 +0.9%	$75.16	$53.89 ▼ $91.53	$3.69B	0.44	951,625 shs	595,207 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	0.00%	+2.49%	-10.73%	-16.92%	+61.13%
OGN Organon & Co.	0.00%	+0.51%	+0.73%	+1.99%	+117.55%
RGC Regencell Bioscience	0.00%	-12.52%	+6.00%	+8.58%	-59.60%
TARS Tarsus Pharmaceuticals	0.00%	+9.75%	-0.81%	+26.78%	+10.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$22.51 -4.1%	$28.28	$10.20 ▼ $37.48	$886.87M	1.31	626,044 shs	484,410 shs
OGN Organon & Co.	$13.83 +0.1%	$13.74	$5.69 ▼ $13.84	$3.63B	1.55	2.28 million shs	1.85 million shs
RGC Regencell Bioscience	$6.71 -2.2%	$6.83	$4.51 ▼ $69.00	$3.33B	1.18	437,837 shs	147,668 shs
TARS Tarsus Pharmaceuticals	$74.85 +0.9%	$75.16	$53.89 ▼ $91.53	$3.69B	0.44	951,625 shs	595,207 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	0.00%	+2.49%	-10.73%	-16.92%	+61.13%
OGN Organon & Co.	0.00%	+0.51%	+0.73%	+1.99%	+117.55%
RGC Regencell Bioscience	0.00%	-12.52%	+6.00%	+8.58%	-59.60%
TARS Tarsus Pharmaceuticals	0.00%	+9.75%	-0.81%	+26.78%	+10.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.64	Moderate Buy	$37.88	68.26% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-17.54% Downside
RGC Regencell Bioscience	1.00	Sell	N/A	N/A
TARS Tarsus Pharmaceuticals	2.80	Moderate Buy	$100.86	34.75% Upside

Current Analyst Ratings Breakdown

Latest ANRO, OGN, TARS, and RGC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/27/2026	ANRO Alto Neuroscience	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/19/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$55.00 ➝ $60.00
10/15/2026	TARS Tarsus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	TARS Tarsus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/8/2026	OGN Organon & Co.	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
10/6/2026	TARS Tarsus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
9/24/2026	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$116.00
9/24/2026	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$116.00
9/21/2026	RGC Regencell Bioscience	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$110.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$110.00

(Data available from 11/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.87 per share	N/A
OGN Organon & Co.	$6.22B	0.58	$5.78 per share	2.39	$2.89 per share	4.78
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.03 per share	N/A
TARS Tarsus Pharmaceuticals	$451.36M	8.18	N/A	N/A	$8.09 per share	9.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-46.46%	-39.09%	11/11/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	18.19	4.03	1.28	3.41%	88.97%	6.03%	11/9/2026 (Estimated)
RGC Regencell Bioscience	-$11.70M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	116.95	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest ANRO, OGN, TARS, and RGC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ANRO Alto Neuroscience	-$0.6735	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	OGN Organon & Co.	$0.88	N/A	N/A	N/A	$1.58 billion	N/A
11/3/2026	Q3 2026	TARS Tarsus Pharmaceuticals	-$1.46	N/A	N/A	N/A	$187.83 million	N/A
10/7/2026	Q4 2026	RGC Regencell Bioscience	N/A	-$0.0060	N/A	-$0.0060	N/A	N/A
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.7345	-$0.65	+$0.0845	-$0.65	N/A	N/A
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest ANRO, OGN, TARS, and RGC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.07	14.85	14.85
OGN Organon & Co.	8.43	1.95	1.44
RGC Regencell Bioscience	N/A	10.77	10.77
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
OGN Organon & Co.	77.43%
RGC Regencell Bioscience	0.13%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.25%
OGN Organon & Co.	1.62%
RGC Regencell Bioscience	2.00%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	68	39.24 million	34.83 million	Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Optionable
RGC Regencell Bioscience	10	495.88 million	485.97 million	Optionable
TARS Tarsus Pharmaceuticals	370	49.30 million	44.55 million	Optionable

ANRO, OGN, TARS, and RGC Headlines

Recent News About These Companies

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Has Average Price Target of $100.86 According to Brokerages

October 30 at 2:28 AM | marketbeat.com

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

October 29 at 4:30 PM | globenewswire.com

Tarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline Planning

October 29 at 7:35 AM | rttnews.com

Tarsus Pharmaceuticals Names Neera Clase Chief Commercial Officer

October 29 at 1:35 AM | visionmonday.comV

Tarsus Makes Neera Clase Permanent CCO

October 28, 2026 | ocbj.comO

Tarsus Pharmaceuticals, Inc. Announces Appointment of Neera Clase as Chief Commercial Officer, Effective November 1, 2026

October 28, 2026 | marketscreener.comM

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

October 28, 2026 | globenewswire.com

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

October 27, 2026 | zacks.com

Tarsus Pharmaceuticals (TARS) Set to Release Quarterly Earnings on Tuesday

October 27, 2026 | marketbeat.com

ETFs Are Net Sellers of Tarsus Pharmaceuticals (TARS) on Oct. 16

October 20, 2026 | finance.yahoo.com

Tarsus Pharmaceuticals, Inc. $TARS Holdings Lowered by Assenagon Asset Management S.A.

October 18, 2026 | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by Zacks Research

October 15, 2026 | marketbeat.com

Bank of America Securities Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)

October 14, 2026 | theglobeandmail.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Climb 3.8% - Time to Buy?

October 12, 2026 | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Moved Down to Strong Sell by Zacks Research

October 8, 2026 | marketbeat.com

Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options

October 6, 2026 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 5, 2026 | marketbeat.com

Tarsus to Present 11 Abstracts at Anaheim Eye Meeting

September 29, 2026 | ocbj.comO

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry ...

September 29, 2026 | markets.businessinsider.com

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

September 29, 2026 | globenewswire.com

Tarsus Pharmaceuticals (TARS) Receives a Buy from Goldman Sachs

September 25, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, OGN, TARS, and RGC Company Descriptions

Alto Neuroscience NYSE:ANRO

$22.51 -0.96 (-4.09%)

Closing price 10/30/2026 03:59 PM Eastern

Extended Trading

$22.57 +0.06 (+0.27%)

As of 10/30/2026 07:30 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Organon & Co. NYSE:OGN

$13.82 +0.02 (+0.11%)

Closing price 10/30/2026 03:59 PM Eastern

Extended Trading

$13.84 +0.01 (+0.07%)

As of 10/30/2026 07:30 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Regencell Bioscience NASDAQ:RGC

$6.71 -0.15 (-2.19%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$6.78 +0.07 (+0.97%)

As of 10/30/2026 07:54 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Tarsus Pharmaceuticals NASDAQ:TARS

$74.85 +0.65 (+0.88%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$76.05 +1.20 (+1.60%)

As of 10/30/2026 07:56 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANRO, OGN, TARS, and RGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANRO, OGN, TARS, and RGC Earnings

Compare Dividends

Latest ANRO, OGN, TARS, and RGC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANRO, OGN, TARS, and RGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, OGN, TARS, and RGC Company Descriptions

Alto Neuroscience NYSE:ANRO

Organon & Co. NYSE:OGN

Regencell Bioscience NASDAQ:RGC

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANRO, OGN, TARS, and RGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANRO, OGN, TARS, and RGC Earnings

Compare Dividends

Latest ANRO, OGN, TARS, and RGC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANRO, OGN, TARS, and RGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, OGN, TARS, and RGC Company Descriptions

Alto Neuroscience NYSE:ANRO

Organon & Co. NYSE:OGN

Regencell Bioscience NASDAQ:RGC

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools